Trial Profile
A phase I trial to investigate DRGT18-2, a novel formulation of Sirolimus (Rapamune)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Aug 2021
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- 09 Oct 2017 New trial record
- 05 Oct 2017 Results presented in a DRGT media release.